References
- Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004; 18:13–16.
- Gupta AK, Medzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology. 2004; 208:89–93.
- Rigopoulos D, Ionnides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: A randomized open-label clinical trial. Br J Dermatol. 2004; 151:1071–1075.
- Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment of seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004; 30:191–195.
- High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol. 2006; 54:1083–8.
- Firooz A, Solhpour AM, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: A randomized, investigator-blind, clinical trial. Arch Dermatol. 2006; 142:1066–1067.
- Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007; 57:257–264.
- De Moraes AP, de Arruda EA, Vitoriano MAV, de Moraes Filho MO, Bezerra FA, de Magalhaes Holanda E, An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrheic dermatitis infected with HIV. J Eur Acad Dermatol Venereol. 2007; 21:596–601.
- Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients. J Korean Med Sci. 2007; 22:868–872.
- Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009; 20:4–9.
- Tatlican S, Eren C, Eskioglu F. Insight into pimecrolimus experience in seborrheic dermatitis:Close follow-up with exact mean cure and remission times and side effect profile. J Dermatolog Treat. 2009; 20:198–202.
- Fritsch PO, Reider N. Other eczematous eruptions. Bolognia JL Jorizzo JL Rapini RPDermatology. Mosby. 215–226.
- Gupta AK, Nicol K, Batra R. 2004; Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2003; 5:417–422.
- Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs. 1988; 36:suppl 5):15–23.
- Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol. 2001; 116:769–773.
- Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: Atopic dermatitis and beyond. Int J Clin Pract. 2005; 59:969–974.
- Sugita T, Tajima M, Tsubuku H, Tsuboi R, Nishikawa A. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother. 2006; 50:2897–2898.